MAYEROVA, Lucie, Peter WOHLFAHRT, Milan SONKA, Zhi CHEN, Josef KAUTZNER, Vojtech MELENOVSKY, Vladimir KARMAZIN, Ivan MALEK, Helena BEDANOVA, Ales TOMASEK, Eva OZÁBALOVÁ, Jan KREJČÍ, Tomas KOVARNIK and Michal PAZDERNIK. Acetylsalicylic acid use and development of cardiac allograft vasculopathy: A national prospective study using highly automated 3-D optical coherence tomography analysis. CLINICAL TRANSPLANTATION. HOBOKEN: WILEY, 2024, vol. 38, No 3, p. 1-11. ISSN 0902-0063. Available from: https://dx.doi.org/10.1111/ctr.15275.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Acetylsalicylic acid use and development of cardiac allograft vasculopathy: A national prospective study using highly automated 3-D optical coherence tomography analysis
Authors MAYEROVA, Lucie (203 Czech Republic), Peter WOHLFAHRT (203 Czech Republic), Milan SONKA (203 Czech Republic), Zhi CHEN, Josef KAUTZNER (203 Czech Republic), Vojtech MELENOVSKY (203 Czech Republic), Vladimir KARMAZIN (203 Czech Republic), Ivan MALEK (203 Czech Republic), Helena BEDANOVA (203 Czech Republic), Ales TOMASEK (203 Czech Republic), Eva OZÁBALOVÁ (203 Czech Republic, belonging to the institution), Jan KREJČÍ (203 Czech Republic, belonging to the institution), Tomas KOVARNIK (203 Czech Republic) and Michal PAZDERNIK (203 Czech Republic).
Edition CLINICAL TRANSPLANTATION, HOBOKEN, WILEY, 2024, 0902-0063.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.100 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1111/ctr.15275
UT WoS 001183729600001
Keywords in English acetylsalicylic acid; cardiac allograft vasculopathy; lipid plaque; OCT
Tags 14110115, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 10/6/2024 13:29.
Abstract
BackgroundThere is conflicting evidence on the role of acetylsalicylic acid (ASA) use in the development of cardiac allograft vasculopathy (CAV).MethodsA nationwide prospective two-center study investigated changes in the coronary artery vasculature by highly automated 3-D optical coherence tomography (OCT) analysis at 1 month and 12 months after heart transplant (HTx). The influence of ASA use on coronary artery microvascular changes was analyzed in the overall study cohort and after propensity score matching for selected clinical CAV risk factors.ResultsIn total, 175 patients (mean age 52 +/- 12 years, 79% male) were recruited. During the 1-year follow-up, both intimal and media thickness progressed, with ASA having no effect on its progression. However, detailed OCT analysis revealed that ASA use was associated with a lower increase in lipid plaque (LP) burden (p = .013), while it did not affect the other observed pathologies. Propensity score matching of 120 patients (60 patient pairs) showed similar results, with ASA use associated with lower progression of LPs (p = .002), while having no impact on layered fibrotic plaque (p = .224), calcification (p = .231), macrophage infiltration (p = .197), or the absolute coronary artery risk score (p = .277). According to Kaplan-Meier analysis, ASA use was not associated with a significant difference in survival (p = .699)ConclusionThis study showed a benefit of early ASA use after HTx on LP progression. However, ASA use did not have any impact on the progression of other OCT-observed pathologies or long-term survival.
PrintDisplayed: 17/7/2024 09:36